PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, March 14, 2016 -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Aviva plc and Aviva Investors Global Services Limited.

The above shareholders have notified Ablynx that they have dropped below the 3% threshold and now hold 901,029 Ablynx shares, which represent 1.64% of the current 55,108,065 outstanding Ablynx shares.

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings: Aviva plc (Parent Company), Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc), Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited), Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited).

Full versions of all transparency notifications are available on Ablynx website, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceutical Co., Ltd. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e:  [email protected]

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  [email protected]
Follow us on Twitter @AblynxABLX

Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t:   +44 (0)20 7866 7905
e:  [email protected]

Belgium/Dutch and French language
Jim Rusagara
Brussels office
t:   +32 (0)2 626 9500
e:  [email protected]

pdf format of the press release http://hugin.info/137912/R/1993813/734103.pdf

HUG#1993813